Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Bad financial results growth rate -41.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-21.1%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield -8.6% (LTM)
  • Share price is 52.7% higher than minimum and 25.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-20.0x vs
    )

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-0.7%)60.55
year average price 51.49  


year start price 52.74 2024-04-02

min close price 39.66 2024-07-05

max close price 63.11 2025-03-10

current price 60.55 2025-04-01
Common stocks: 2 111 517 922

Dividend Yield:  4.0%
FCF Yield LTM: -8.6%
EV / LTM EBITDA: -20.0x
EV / EBITDA annualized: 240.2x
Last revenue growth (y/y):  +7.5%
Last growth of EBITDA (y/y):  -89.5%
Historical revenue growth:  +1.5%
Historical growth of EBITDA:  -43.7%
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 127 852
Net Debt ($m): 39 356
EV (Enterprise Value): 167 208
EBITDA LTM ($m): -8 379
EV / LTM EBITDA: -20.0x
Price to Book: 7.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-01zacks.com

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

2025-03-20247wallst.com

BofA Securities Says No Rate Cuts in 2025 or 2026: Grab These High-Yield Dividend Blue Chips Now

2025-03-18seekingalpha.com

Bristol-Myers Squibb: Why I'm Still Bullish

2025-03-12seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)

2025-03-11prnewswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

2025-03-10businesswire.com

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2025-03-08businesswire.com

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

2025-03-06zacks.com

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

2025-03-04accessnewswire.com

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

2025-02-28247wallst.com

The Artificial Intelligence Party Over for Now? Safe 4%+ High-Yield Dividend Blue Chips Are On Sale
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data